Ex­clu­sive: Au­toim­mune CAR-T biotech Kyver­na Ther­a­peu­tics is con­sid­er­ing an IPO next month

Kyver­na Ther­a­peu­tics, one of the clin­i­cal-stage biotechs at the fore­front of CAR-T cell ther­a­py’s ex­pan­sion in­to au­toim­mune dis­eases, is con­sid­er­ing an IPO as ear­ly as next month, peo­ple fa­mil­iar with the com­pa­ny’s think­ing told End­points News.

The Cal­i­for­nia biotech could seek a list­ing short­ly be­fore Valen­tine’s Day, ac­cord­ing to the in­di­vid­u­als, who asked not to be iden­ti­fied to dis­cuss con­fi­den­tial mat­ters. The com­pa­ny could re­veal its IPO fil­ing as ear­ly as next week, though it’s al­so pos­si­ble that plans could change.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.